Actinogen Medical Ltd
ACW
Company Profile
Business description
Actinogen Medical Ltd is a biotechnology company. The company develops a novel therapy for neurological and neuropsychiatric diseases associated with dysregulated cortisol in the brain. It is focused on the clinical development of Xanamem, an oral medication for neurological diseases amenable to its mechanism of lowering cortisol in brain cells. Geographically, the company's income is derived in Australia.
Contact
109 Pitt Street
Level 9, Suite 901
SydneyNSW2000
AUST: +61 289647401
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
Stocks News & Analysis
stocks
The trillion-dollar club: Are these mega-sized stocks still buys?
The biggest stocks got bigger this year, breaking multi-trillion-dollar milestones.
stocks
New pricing model for embattled ASX tech leader
Investor day shows off potentially disruptive pricing model.
stocks
Chart of the Week: We see opportunity in Mineral Resources despite debt concerns
Shares trade at a discount despite attractive longer-term outlook.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,926.10 | 19.30 | 0.22% |
| CAC 40 | 8,122.03 | 34.61 | 0.43% |
| DAX 40 | 23,882.03 | 188.32 | 0.79% |
| Dow JONES (US) | 47,850.94 | 31.96 | -0.07% |
| FTSE 100 | 9,710.87 | 18.80 | 0.19% |
| HKSE | 26,080.46 | 144.56 | 0.56% |
| NASDAQ | 23,505.14 | 51.04 | 0.22% |
| Nikkei 225 | 50,491.87 | 536.55 | -1.05% |
| NZX 50 Index | 13,483.99 | 31.63 | -0.23% |
| S&P 500 | 6,857.12 | 7.40 | 0.11% |
| S&P/ASX 200 | 8,634.60 | 20.50 | 0.24% |
| SSE Composite Index | 3,903.32 | 27.53 | 0.71% |